Senores Pharma to buy Apnar Pharma at enterprise value of Rs 91 crore
Ahmedabad: Senores Pharma has announced that the Company has entered into a Share Purchase Agreement for acquisition of 100 percent share capital of Apnar Pharma in two tranches.
Upon consummation of the acquisition, Apnar Pharma shall become a wholly owned subsidiary of the Company.
The acquisition of 100% equity shares in the Apnar Pharma at total enterprise value is Rs. 91 crores. Of this, Rs 76 crores comprises total debt plus excepted liabilities related to the Plant to be taken over by Senores. The remaining Rs 15 crores will be paid in cash in two tranches, with 75% payable in the first tranche and 25% in the second tranche.
1st Tranche of the Transaction to be completed in current fiscal by March 2026 and 2nd tranche is expected to complete by Q2 of FY 2027.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.